Technology Catalysts International
username
client login
password
Technology Catalysts International is a multinational consulting company specializing in technology licensing and assessment, small company acquisitions, technical and business research.
Technology Catalysts
Technology Catalysts

Multi-Client Reports

Next-Generation Self-Administered Drug-Device Combinations
New Technologies and Business Opportunities


Drug-device combination products are emerging as a novel delivery mechanism for biologics and new classes of pharmaceuticals. The biologics market is poised for future growth due to an aging global population, increasing incidence of chronic indications, and a growing number of biologic products in late-stage clinical development. Current biologic therapies are delivered by injection using traditional needle and syringes, which require administration by a healthcare professional, have a high risk of needlestick injury, and are painful to the patient. As the pharmaceutical industry moves towards more patient-friendly therapies, self-administered drug-device combination products are being investigated as a novel alternative to traditional injection devices for the delivery of biologics.

Technology Catalysts International has developed a report that analyzes the current technology and market potential for next-generation self-administered drug-device combinations. This report features an overview of drug-device combination products with a focus on self-injection devices (e.g., autoinjectors, pen injectors, and prefilled syringes), active transdermal devices (e.g., microneedles), and inhalers. The report also provides insight into regulatory challenges for drug-device combination products in the US, EU, and Japan. Additionally, over 70 drug-device combination technologies available for license are profiled. This report should be of strong value to pharma companies developing biopharmaceutical products and innovative delivery devices to help them differentiate their products or generic companies developing biosimilars and biobetters.

Key information presented in the report includes:

  • Product and Technology Introduction
    • Overview of drug-device combination products
    • Advantages and challenges with different drug-device combinations
    • Analysis of therapeutic trends
  • Market Landscape Analysis of Drug-Device Combinations
    • Sales of leading drug-device combination products in 2011
    • Pipeline products and market forecasts
  • Regulatory Requirements for Drug-Device Combinations
    • Recent published guidance
    • Allergy
  • Technology Licensing Opportunities
    • Detailed profiles of drug-device combination technologies
    • Updated contact information to initiate licensing agreements






Download a Brochure
(PDF: 1.2MB / 2 pages)



For additional information, please contact:

Ajay Rastogi
Vice President
Telephone: (703) 531-0257
Facsimile: (703) 237-0042
E-mail: Ajay Rastogi

or

Sandra E. Erb
Vice President, Research
Telephone: (703) 531-0247
Facsimile: (703) 237-0042
E-mail: Sandra E. Erb
Technology Catalysts
Technology Catalysts Technology Catalysts Technology Catalysts Technology Catalysts




Contact Us | Privacy | Sitemap Copyright © 2014 Technology Catalysts International Technology Catalysts